WELCOME TO JOHNS HOPKINS HEALTH ALERTS!

This free public service from Johns Hopkins Medicine helps keep you up to date on the latest breakthroughs for the most common medical conditions which prevent healthy aging. Browse all the articles via the Health Alert Topics navigation bar on the right, or read the headlines below.


Get the latest news sent straight to your Inbox. Register now for your FREE Johns Hopkins Health Alerts. Check the boxes below for all the topics you are interested in, enter your email address, and click "Send." It's fast, easy, and FREE.   Benefits of Being A Registered User

Enter your email here: (Example: yourname@domain.com)
Please send my alerts as:

We value your privacy and will never rent your email address.Already a Member? Manage your Health Alerts


Johns Hopkins Health Alert

New Approach to Slow Diabetic Kidney Disease

Comments (0)

A study reported in The New England Journal of Medicine (volume 358, page 2433) sheds light on a promising new approach that is effective for treating diabetic nephropathy (kidney disease) -- a complication of long-term diabetes.

About 30 to 40% of people with type 1 diabetes and 20% of those with type 2 diabetes eventually develop some kidney damage, though by no means do all of them go on to kidney failure. The damage occurs in tiny blood vessels throughout the kidneys, which act as filters to remove waste products from the bloodstream.

High blood pressure (hypertension) worsens kidney disease (nephropathy), so controlling hypertension is an essential part of managing diabetic nephropathy. For many people, existing antihypertensive drugs fail to slow kidney damage, but the new drug aliskiren (Tekturna) may offer much-needed additional protection.

Researchers randomized a group of 599 people with diabetes, hypertension, and kidney disease: Half took 150 mg of Tekturna daily for three months, then 300 mg a day for the next three months; the other half received placebos. All took the antihypertensive drug losartan (Cozaar) in addition to drugs to lower blood pressure.

Participants taking Tekturna had reduced proteinuria (loss of protein in the urine) -- a sign of failing kidneys -- by 20%, on average. In addition, almost 25% of the Tekturna takers had a 50% reduction in protein loss in urine, compared with 13% of the placebo group. Little difference in blood pressure was seen between the two groups.

Many common antihypertensive drugs work by interfering with angiotensin, a chemical that raises blood pressure by constricting blood vessels. Tekturna also blocks renin, the enzyme that produces angiotensin.

Posted in Diabetes on November 12, 2009
Reviewed February 2011


Medical Disclaimer: This information is not intended to substitute for the advice of a physician. Click here for additional information: Johns Hopkins Health Alerts Disclaimer


Notify Me

Would you like us to inform you when we post new Diabetes Health Alerts?

Post a Comment

Comments

Health Alerts registered users may post comments and share experiences here at their own discretion. We regret that questions on individual health concerns to the Johns Hopkins editors cannot be answered in this space.

The views expressed here do not constitute medical advice, and do not represent the position of Johns Hopkins Medicine or Remedy Health Media, LLC, which has no responsibility for any comments posted on this site.


Post a Comment


Already a subscriber?

Login

Forgot your password?

New to Johns Hopkins Health Alerts?

Register to submit your comments.

(example: yourname@domain.com)

(800) 829-0422

Registered Users Log-in:

Forgot Password?

Become a Registered User!
It's fast and FREE!
The Benefits of Being a Registered User

Health Topic Pages

  • Health Alert
  • Special Report

What is this?

XML


Johns Hopkins’ Diabetes Bestsellers

Our Featured Title:

Johns Hopkins White Paper 2011: Diabetes


Related Titles: